TW201825119A - 使用抗ccr4抗體及抗pd-1抗體治療癌症之方法 - Google Patents

使用抗ccr4抗體及抗pd-1抗體治療癌症之方法 Download PDF

Info

Publication number
TW201825119A
TW201825119A TW106142006A TW106142006A TW201825119A TW 201825119 A TW201825119 A TW 201825119A TW 106142006 A TW106142006 A TW 106142006A TW 106142006 A TW106142006 A TW 106142006A TW 201825119 A TW201825119 A TW 201825119A
Authority
TW
Taiwan
Prior art keywords
cancer
antibody
seq
set forth
sequence set
Prior art date
Application number
TW106142006A
Other languages
English (en)
Chinese (zh)
Inventor
川上哲義
大山行也
玄元一人
亞蘭 J 寇曼
尼爾斯 隆伯格
新达 郑
史帝芬 D 艾爾布奇
瑪格麗特 馬歇爾
丹尼斯 海利
Original Assignee
日商協和醱酵麒麟有限公司
日商小野藥品工業股份有限公司
美商必治妥美雅史谷比公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 日商協和醱酵麒麟有限公司, 日商小野藥品工業股份有限公司, 美商必治妥美雅史谷比公司 filed Critical 日商協和醱酵麒麟有限公司
Publication of TW201825119A publication Critical patent/TW201825119A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
TW106142006A 2016-11-30 2017-11-30 使用抗ccr4抗體及抗pd-1抗體治療癌症之方法 TW201825119A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662428468P 2016-11-30 2016-11-30
US62/428,468 2016-11-30
US201762554486P 2017-09-05 2017-09-05
US62/554,486 2017-09-05

Publications (1)

Publication Number Publication Date
TW201825119A true TW201825119A (zh) 2018-07-16

Family

ID=60888559

Family Applications (1)

Application Number Title Priority Date Filing Date
TW106142006A TW201825119A (zh) 2016-11-30 2017-11-30 使用抗ccr4抗體及抗pd-1抗體治療癌症之方法

Country Status (2)

Country Link
TW (1) TW201825119A (fr)
WO (1) WO2018101448A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2652664T3 (es) 2011-12-01 2018-02-05 Chemocentryx, Inc. Anilinas sustituidas como antagonistas de CCR(4)
WO2017011580A2 (fr) 2015-07-13 2017-01-19 Cytomx Therapeutics, Inc. Anticorps anti-pd-1, anticorps anti-pd-1 activables, et leurs procédés d'utilisation
IL280831B2 (en) 2018-08-29 2024-05-01 Chemocentryx Inc Combination therapy with C-C antagonists such as cytokine receptor 4 (CCR4) and one or more immune checkpoint inhibitors

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
ES2571230T3 (es) 1999-04-09 2016-05-24 Kyowa Hakko Kirin Co Ltd Procedimiento para controlar la actividad de una molécula inmunofuncional
PL354286A1 (en) 1999-08-23 2003-12-29 Dana-Farber Cancer Institutedana-Farber Cancer Institute Pd-1, a receptor for b7-4, and uses therefor
EP3263702A1 (fr) 2000-10-06 2018-01-03 Kyowa Hakko Kirin Co., Ltd. Compositions d'anticorps produisant des cellules
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
ES2367430T3 (es) 2002-12-23 2011-11-03 Wyeth Llc Anticuerpos contra pd-1 y sus usos.
WO2005035586A1 (fr) 2003-10-08 2005-04-21 Kyowa Hakko Kogyo Co., Ltd. Composition proteique hybride
DE602005015542D1 (de) 2004-01-12 2009-09-03 Applied Molecular Evolution Varianten der fc-region
US20060034841A1 (en) 2004-06-07 2006-02-16 Kyowa Hakko Kogyo Co., Ltd. Method of depleting regulatory T cell
RU2406760C3 (ru) 2005-05-09 2017-11-28 Оно Фармасьютикал Ко., Лтд. Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами
US7923538B2 (en) 2005-07-22 2011-04-12 Kyowa Hakko Kirin Co., Ltd Recombinant antibody composition
SI2170959T1 (sl) 2007-06-18 2014-04-30 Merck Sharp & Dohme B.V. Protitelesa proti receptorjem pd-1 za humano programirano smrt
EP2262837A4 (fr) 2008-03-12 2011-04-06 Merck Sharp & Dohme Protéines de liaison avec pd-1
SI2350129T1 (sl) 2008-08-25 2015-11-30 Amplimmune, Inc. Sestavki PD-1 antagonistov in postopek njihove uporabe
RU2625034C2 (ru) 2011-04-20 2017-07-11 МЕДИММЬЮН, ЭлЭлСи Антитела и другие молекулы, которые связывают в7-н1 и pd-1
KR102193343B1 (ko) 2012-05-15 2020-12-22 브리스톨-마이어스 스큅 컴퍼니 Pd-1/pd-l1 신호전달을 방해하는 것에 의한 암 면역요법

Also Published As

Publication number Publication date
WO2018101448A1 (fr) 2018-06-07

Similar Documents

Publication Publication Date Title
KR102606252B1 (ko) 항-pd-1 항체로 암을 치료하는 방법
CN106103486B (zh) 抗ox40抗体和使用方法
US11866509B2 (en) Humanized antibodies against CEACAM1
JP6552621B2 (ja) 抗ｐｄ−１抗体およびその使用方法
JP5130044B2 (ja) ４ｉｇ−ｂ７−ｈ３およびその対応するｎｋ細胞受容体を標的化する治療および診断方法ならびに組成物
JP2018521019A (ja) 抗ｏｘ４０抗体を使用して癌を治療する方法
KR20170074246A (ko) Ox40 효능제 치료의 효능 예측 및 평가용 방법 및 바이오마커
CN108350505A (zh) 用于测定icos表达的基因标志
TW201622748A (zh) 用於治療贅瘤形成之治療組合及方法
KR20190008962A (ko) 림프종 치료에서의 항-cd30 항체와 조합된 항-pd-1 항체의 용도
WO2021228178A1 (fr) Compositions et méthodes pour le traitement du cancer
CN111094982A (zh) 用于治疗和诊断癌症的tim-3拮抗剂
Borrie et al. T Lymphocyte–Based Cancer Immunotherapeutics
US20230131598A1 (en) Combination treatment for cancer
CN109475633A (zh) 在难治性霍奇金淋巴瘤中用纳武单抗阻断pd-1
TW201825119A (zh) 使用抗ccr4抗體及抗pd-1抗體治療癌症之方法
JP2023554422A (ja) がんの治療のための多重特異性抗体
EP3765519B1 (fr) Anticorps anti-cxcr4 combiné à des cellules tueuses naturelles activées et développées pour une immunothérapie anticancéreuse
CN110603447A (zh) 用抗肾酶抗体和抗pd1抗体治疗癌症的组合物和方法
US20240092934A1 (en) Assessment of ceacam1 expression on tumor infiltrating lymphocytes
US20230365691A1 (en) Use of anti-pd-1 antibody in treatment of nasopharyngeal carcinoma
WO2023076989A1 (fr) Méthodes de traitement du cancer à l'aide d'une association d'un anticorps anti-pd-1 et d'un conjugué anticorps anti-cd30-médicament
AU2021256925A1 (en) Combination treatment for cancer based upon an ICOS antibody and a PD-L1 antibody TGF-beta-receptor fusion protein
JP2023521228A (ja) 癌の併用療法